JP2015525216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525216A5 JP2015525216A5 JP2015516219A JP2015516219A JP2015525216A5 JP 2015525216 A5 JP2015525216 A5 JP 2015525216A5 JP 2015516219 A JP2015516219 A JP 2015516219A JP 2015516219 A JP2015516219 A JP 2015516219A JP 2015525216 A5 JP2015525216 A5 JP 2015525216A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion
- mucin
- fusion protein
- amino acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 108020001507 fusion proteins Proteins 0.000 claims 19
- 102000037865 fusion proteins Human genes 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- -1 sTNFR2 Proteins 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- 102100020997 Fractalkine Human genes 0.000 claims 2
- 102000028180 Glycophorins Human genes 0.000 claims 2
- 108091005250 Glycophorins Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101000623897 Homo sapiens Mucin-12 Proteins 0.000 claims 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 102100039564 Leukosialin Human genes 0.000 claims 2
- 102100023143 Mucin-12 Human genes 0.000 claims 2
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 2
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 claims 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims 1
- 102100026425 Adhesion G protein-coupled receptor E3 Human genes 0.000 claims 1
- 102100036792 Adhesion G protein-coupled receptor L4 Human genes 0.000 claims 1
- 102400000310 Alpha-dystroglycan Human genes 0.000 claims 1
- 108010009575 CD55 Antigens Proteins 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 108010071885 Dystroglycans Proteins 0.000 claims 1
- 108010024212 E-Selectin Proteins 0.000 claims 1
- 102100023471 E-selectin Human genes 0.000 claims 1
- 102100038083 Endosialin Human genes 0.000 claims 1
- 101710144543 Endosialin Proteins 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102400000446 Glycocalicin Human genes 0.000 claims 1
- 101800001015 Glycocalicin Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 claims 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 claims 1
- 101000718235 Homo sapiens Adhesion G protein-coupled receptor E3 Proteins 0.000 claims 1
- 101000928172 Homo sapiens Adhesion G protein-coupled receptor L4 Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000623900 Homo sapiens Mucin-13 Proteins 0.000 claims 1
- 101000623905 Homo sapiens Mucin-15 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101001133059 Homo sapiens Mucin-19 Proteins 0.000 claims 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 1
- 101001133091 Homo sapiens Mucin-20 Proteins 0.000 claims 1
- 101001133088 Homo sapiens Mucin-21 Proteins 0.000 claims 1
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims 1
- 101000972285 Homo sapiens Mucin-3B Proteins 0.000 claims 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 1
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 claims 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims 1
- 101000972273 Homo sapiens Mucin-7 Proteins 0.000 claims 1
- 101001121378 Homo sapiens Oviduct-specific glycoprotein Proteins 0.000 claims 1
- 101000718237 Homo sapiens Putative adhesion G protein-coupled receptor E4P Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000976442 Homo sapiens Zona pellucida sperm-binding protein 3 Proteins 0.000 claims 1
- 108010092694 L-Selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 108010005832 Leukosialin Proteins 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100023124 Mucin-13 Human genes 0.000 claims 1
- 102100023128 Mucin-15 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100023125 Mucin-17 Human genes 0.000 claims 1
- 102100034257 Mucin-19 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 102100034242 Mucin-20 Human genes 0.000 claims 1
- 102100034260 Mucin-21 Human genes 0.000 claims 1
- 102100022497 Mucin-3A Human genes 0.000 claims 1
- 102100022702 Mucin-3B Human genes 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 102100022496 Mucin-5AC Human genes 0.000 claims 1
- 102100022494 Mucin-5B Human genes 0.000 claims 1
- 102100022493 Mucin-6 Human genes 0.000 claims 1
- 102100022492 Mucin-7 Human genes 0.000 claims 1
- 108010063954 Mucins Proteins 0.000 claims 1
- 102000015728 Mucins Human genes 0.000 claims 1
- 102100026327 Oviduct-specific glycoprotein Human genes 0.000 claims 1
- 108010035766 P-Selectin Proteins 0.000 claims 1
- 102100023472 P-selectin Human genes 0.000 claims 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 108010054395 P-selectin ligand protein Proteins 0.000 claims 1
- 102100024588 Podocalyxin-like protein 2 Human genes 0.000 claims 1
- 108091010857 Podocalyxin-like protein 2 Proteins 0.000 claims 1
- 102100026426 Putative adhesion G protein-coupled receptor E4P Human genes 0.000 claims 1
- 102100028688 Putative glycosylation-dependent cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100034258 Sialomucin core protein 24 Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004401 podocalyxin Human genes 0.000 claims 1
- 108090000917 podocalyxin Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108010012704 sulfated glycoprotein p50 Proteins 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657378P | 2012-06-08 | 2012-06-08 | |
| US201261657285P | 2012-06-08 | 2012-06-08 | |
| US201261657264P | 2012-06-08 | 2012-06-08 | |
| US61/657,285 | 2012-06-08 | ||
| US61/657,378 | 2012-06-08 | ||
| US61/657,264 | 2012-06-08 | ||
| US201261723081P | 2012-11-06 | 2012-11-06 | |
| US61/723,081 | 2012-11-06 | ||
| US201361778575P | 2013-03-13 | 2013-03-13 | |
| US201361778812P | 2013-03-13 | 2013-03-13 | |
| US61/778,812 | 2013-03-13 | ||
| US61/778,575 | 2013-03-13 | ||
| PCT/US2013/044551 WO2013184938A2 (en) | 2012-06-08 | 2013-06-06 | Fusion polypeptides comprising mucin-domain polypeptide linkers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525216A JP2015525216A (ja) | 2015-09-03 |
| JP2015525216A5 true JP2015525216A5 (https=) | 2016-07-28 |
| JP6322626B2 JP6322626B2 (ja) | 2018-05-09 |
Family
ID=49712642
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516219A Expired - Fee Related JP6322626B2 (ja) | 2012-06-08 | 2013-06-06 | ムチン−ドメインポリペプチドリンカーを含む融合ポリペプチド |
| JP2015516220A Expired - Fee Related JP6234446B2 (ja) | 2012-06-08 | 2013-06-06 | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| JP2015516221A Active JP6388408B2 (ja) | 2012-06-08 | 2013-06-06 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2017151506A Active JP6545759B2 (ja) | 2012-06-08 | 2017-08-04 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2019113671A Active JP7048543B2 (ja) | 2012-06-08 | 2019-06-19 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2021195887A Active JP7350041B2 (ja) | 2012-06-08 | 2021-12-02 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2023085990A Ceased JP2023109948A (ja) | 2012-06-08 | 2023-05-25 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516220A Expired - Fee Related JP6234446B2 (ja) | 2012-06-08 | 2013-06-06 | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| JP2015516221A Active JP6388408B2 (ja) | 2012-06-08 | 2013-06-06 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2017151506A Active JP6545759B2 (ja) | 2012-06-08 | 2017-08-04 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2019113671A Active JP7048543B2 (ja) | 2012-06-08 | 2019-06-19 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2021195887A Active JP7350041B2 (ja) | 2012-06-08 | 2021-12-02 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2023085990A Ceased JP2023109948A (ja) | 2012-06-08 | 2023-05-25 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9156897B2 (https=) |
| EP (5) | EP2859015B1 (https=) |
| JP (7) | JP6322626B2 (https=) |
| AU (3) | AU2013271545C1 (https=) |
| CA (3) | CA2869787C (https=) |
| CY (2) | CY1120522T1 (https=) |
| DK (2) | DK2859015T3 (https=) |
| ES (4) | ES2675568T3 (https=) |
| HR (2) | HRP20180914T1 (https=) |
| HU (2) | HUE037849T2 (https=) |
| LT (2) | LT3401402T (https=) |
| ME (1) | ME03079B (https=) |
| NZ (4) | NZ630851A (https=) |
| PL (2) | PL2859015T3 (https=) |
| PT (2) | PT2859015T (https=) |
| RS (2) | RS57369B1 (https=) |
| SI (2) | SI2859015T1 (https=) |
| SM (2) | SMT201800363T1 (https=) |
| TR (2) | TR201809046T4 (https=) |
| WO (3) | WO2013184938A2 (https=) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| WO2017120589A1 (en) * | 2016-01-08 | 2017-07-13 | Washington University | Compositions comprising chemerin and methods of use thereof |
| WO2018005226A2 (en) * | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| WO2018011803A1 (en) | 2016-07-11 | 2018-01-18 | The National Institute for Biotechnology in the Negev Ltd. | Fusion proteins with extended serum half life |
| US11524985B2 (en) | 2017-03-20 | 2022-12-13 | Bio-Techne Corporation | IL-37 fusion protein and methods of making and using same |
| KR101784288B1 (ko) * | 2017-04-26 | 2017-10-11 | (주)넥스젠바이오텍 | 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 열 충격 단백질 10의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
| KR101800200B1 (ko) * | 2017-05-26 | 2017-11-23 | (주)넥스젠바이오텍 | 항산화 활성 및 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 상피세포 성장인자의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
| CN117737045A (zh) | 2017-06-27 | 2024-03-22 | 科德克希思公司 | 青霉素g酰化酶 |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
| PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| KR102194644B1 (ko) * | 2018-04-26 | 2020-12-24 | 주식회사 굳티셀 | 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN108948178A (zh) * | 2018-07-20 | 2018-12-07 | 安他杰（杭州）生物医药科技有限公司 | 一种改良的人il-37蛋白及其应用 |
| CN109251896A (zh) * | 2018-08-13 | 2019-01-22 | 中山大学 | 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| JP7355326B2 (ja) * | 2019-08-05 | 2023-10-03 | デンカ株式会社 | 経粘膜投与薬剤 |
| BR112022007158A2 (pt) * | 2019-10-18 | 2022-07-05 | Alkermes Pharma Ireland Ltd | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| EP4085077A4 (en) * | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| EP4093755A4 (en) * | 2020-01-24 | 2024-07-31 | Alkermes Pharma Ireland Limited | PURIFICATION PROCESSES |
| CN116057176A (zh) * | 2020-03-21 | 2023-05-02 | 赖瑞克斯生物科技公司 | Ace2和补体途径的双特异性和三特异性功能分子及其用途 |
| KR20230016178A (ko) | 2020-04-15 | 2023-02-01 | 엘커메스 파마 아일랜드 리미티드 | 혈관신생 억제제와 조합된 면역자극제 |
| CN115916241A (zh) * | 2020-04-15 | 2023-04-04 | 奥克梅斯制药爱尔兰有限公司 | 与血管生成抑制剂组合的免疫刺激剂 |
| CN115997008A (zh) | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
| CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US20210395325A1 (en) * | 2020-05-11 | 2021-12-23 | Alkermes Pharma Ireland Limited | Il-2 fusion polypeptide compositions and methods of making and using the same |
| KR20230009446A (ko) * | 2020-05-11 | 2023-01-17 | 엘커메스 파마 아일랜드 리미티드 | Il-2 융합 폴리펩티드 조성물 및 그의 제조 및 사용 방법 |
| CN111662973B (zh) * | 2020-05-28 | 2023-08-25 | 广州医科大学附属第一医院（广州呼吸中心） | 与慢性阻塞性肺疾病易感性辅助诊断相关的snp位点及其应用 |
| WO2022007885A1 (zh) * | 2020-07-08 | 2022-01-13 | 南京师范大学 | 融合多肽和多肽二聚体及其用途 |
| CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
| WO2022026358A1 (en) * | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| WO2022098954A1 (en) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Tlr agonist compounds and related cancer immunotherapy methods |
| WO2022099695A1 (en) * | 2020-11-16 | 2022-05-19 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Cd164 fusion and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| EP4259164A1 (en) | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| EP4262827A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP2024501845A (ja) | 2020-12-31 | 2024-01-16 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| EP4301138A2 (en) | 2021-03-05 | 2024-01-10 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| US20240191191A1 (en) | 2021-03-19 | 2024-06-13 | Iovance Biotherapeutics, Inc. | Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| MX2023011268A (es) | 2021-03-24 | 2023-12-14 | Alkermes Inc | Anticuerpos upar y proteínas de fusión con estos. |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| CA3215830A1 (en) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4373270A2 (en) | 2021-07-22 | 2024-05-29 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
| JP2024527961A (ja) | 2021-07-28 | 2024-07-26 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療 |
| CN113735980A (zh) * | 2021-08-23 | 2021-12-03 | 中国医学科学院北京协和医院 | 一种自融合串联蛋白修饰方法及其应用 |
| WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| US20250000903A1 (en) | 2021-09-24 | 2025-01-02 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CA3243416A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS |
| EP4469065A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| KR102798377B1 (ko) * | 2022-04-26 | 2025-04-22 | 전남대학교산학협력단 | 원형순열에 기반한 기능성 재조합 인간 섬유아세포 성장인자 7의 제조방법 및 그 용도 |
| CA3251533A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST |
| WO2023235790A1 (en) * | 2022-06-01 | 2023-12-07 | University Of Miami | Bifunctional il-2 and il-10 fusion proteins and uses thereof |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| CN117003852B (zh) * | 2022-07-07 | 2024-11-05 | 北京大学 | 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用 |
| US20260021181A1 (en) | 2022-08-01 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583889A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| CN117106024B (zh) * | 2022-10-21 | 2024-05-24 | 南京市妇幼保健院 | 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用 |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| JP2025539816A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| JP2026501338A (ja) * | 2022-12-22 | 2026-01-14 | アナヴェオン アーゲー | 抗ｐｄ－１抗体抗原結合ドメイン及び免疫抱合体 |
| EP4431525A1 (en) | 2023-03-16 | 2024-09-18 | Anaveon AG | Il-2 fusion protein |
| KR20250135294A (ko) * | 2023-02-21 | 2025-09-12 | 레메젠 코, 리미티드 | 암을 위한 il-15 작용제 |
| WO2025015318A2 (en) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| AU2023455215A1 (en) * | 2023-07-25 | 2026-02-05 | Zahav Bioscience Llc | Cytokine compositions and methods of use thereof |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025085672A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
| WO2026006784A1 (en) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Methods of making tumor reactive peripheral blood lymphocytes (trpbl) |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| WO2026072794A2 (en) | 2024-09-26 | 2026-04-02 | Iovance Biotherapeutics, Inc. | Expansion processes for til product enriched with neoantigen- reactive t cells (narts) |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| US5840496A (en) | 1990-10-09 | 1998-11-24 | Chiron Corporation | Method for diagnosing endometrial cancer |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| US5837495A (en) | 1994-10-13 | 1998-11-17 | Applied Research Systems Ars Holding N.V. | DNA encoding interleukin-1 antagonist |
| US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| ATE252372T1 (de) | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
| AU721196B2 (en) | 1996-10-25 | 2000-06-29 | G.D. Searle & Co. | Circularly permuted erythropoietin receptor agonists |
| US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP1027373B1 (en) * | 1997-10-31 | 2006-09-06 | Biomira, Inc. | Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression |
| WO1999046392A1 (en) * | 1998-03-12 | 1999-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| EP1066322A1 (en) * | 1998-04-03 | 2001-01-10 | The University of Washington | Circularly permuted biotin binding proteins |
| CN1736502A (zh) | 1999-03-03 | 2006-02-22 | 奥普蒂诺斯公司 | 鼻传送装置 |
| US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2391080A1 (en) * | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| CA2397162A1 (en) | 2000-01-13 | 2001-07-19 | Kalobios, Inc. | Circularly permutated, interaction-activated proteins |
| US6497870B1 (en) | 2000-05-22 | 2002-12-24 | Hyseq, Inc. | Therapeutic uses of il-1 receptor antagonist |
| EP1290170A2 (en) | 2000-06-16 | 2003-03-12 | Asterion Limited | Binding agents: chimeric ligand/receptor proteins |
| AU9184901A (en) | 2000-09-14 | 2002-03-26 | Ares Trading Sa | Use of il-6r/il-6 chimera in huntington's disease |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| JP2004519230A (ja) | 2001-02-06 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ） |
| CA2454469A1 (en) * | 2001-07-20 | 2003-02-06 | Absorber, Ab | Blood group antigen fusion polypeptides and methods of use thereof |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| IL147412A0 (en) * | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | The use of il6r/il6 chimera in nerve cell regeneration |
| SI1499729T1 (sl) * | 2002-04-18 | 2011-11-30 | Yeda Res & Dev | Derivati encima ki inducira nf-kappab njihova priprava in uporaba |
| EP1517700B1 (en) | 2002-04-22 | 2012-03-28 | Recopharma AB | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| EP1534748A2 (en) * | 2002-08-09 | 2005-06-01 | Recopharma AB | Fusion proteins and methods of producing same |
| US20040175359A1 (en) | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
| WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| GB0315182D0 (en) | 2003-06-28 | 2003-08-06 | Asterion Ltd | Cytokine variant polypeptides |
| WO2005034863A2 (en) * | 2003-10-03 | 2005-04-21 | Jarikuma Corporation | Countermeasures against malaria |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| US8338138B2 (en) | 2004-01-28 | 2012-12-25 | The John Hopkins University | Methods for making and using molecular switches involving circular permutation |
| RS57852B1 (sr) | 2004-04-02 | 2018-12-31 | Swedish Orphan Biovitrum Ab Publ | Postupci za smanjenje agregacije il-1ra |
| US7700318B2 (en) | 2004-08-25 | 2010-04-20 | Amprotein Corporation | Chimeric polypeptide and use thereof |
| MX2007006214A (es) * | 2004-11-24 | 2008-04-16 | Therakine Ltd | Un implante para suministro de farmaco intraocular. |
| WO2006086607A2 (en) | 2005-02-10 | 2006-08-17 | Emory University | Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation |
| CA2618791C (en) * | 2005-08-12 | 2014-05-13 | Riken | Novel mucin-type glycoprotein and use thereof |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20100016547A1 (en) * | 2005-11-30 | 2010-01-21 | Takaomi Ito | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient |
| DE602005015733D1 (de) * | 2005-12-02 | 2009-09-10 | Apceth Gmbh & Co Kg | Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration |
| GB0606946D0 (en) | 2006-04-06 | 2006-05-17 | Asterion Ltd | Polypeptide antagonist |
| US20100063258A1 (en) | 2006-06-28 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion protein constructs |
| MX2009006398A (es) * | 2006-12-12 | 2009-06-23 | Biorexis Pharmaceutical Corp | Genotecas de proteinas de fusion de transferrina. |
| US7816324B2 (en) | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| WO2008133928A2 (en) * | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
| NZ599338A (en) * | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| DE102007049830A1 (de) | 2007-10-16 | 2009-04-23 | Henkel Ag & Co. Kgaa | Neue Proteinvarianten durch zirkulare Permutation |
| EP2050759A1 (en) | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| MY152003A (en) * | 2008-05-29 | 2014-08-15 | Univ Leland Stanford Junior | Cell line, system and method for optical control of secondary messengers |
| US8765669B2 (en) * | 2008-06-17 | 2014-07-01 | Glytech, Inc. | Glycosylated GLP-1 peptide |
| GB0815216D0 (en) * | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| WO2011103049A2 (en) * | 2010-02-16 | 2011-08-25 | Immune Disease Institute, Inc. | Method for screening receptors/ligands interactions |
| EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| US9119869B2 (en) | 2010-04-29 | 2015-09-01 | Ronald J. Shebuski | Mucin derived polypeptides |
| ES2952394T3 (es) * | 2010-07-29 | 2023-10-31 | Buzzard Pharmaceuticals AB | Antagonistas quiméricos del receptor IL-1 de tipo I |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| US9511151B2 (en) * | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| EP2851429B1 (en) * | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
-
2013
- 2013-06-06 US US13/911,818 patent/US9156897B2/en active Active
- 2013-06-06 CA CA2869787A patent/CA2869787C/en active Active
- 2013-06-06 US US13/911,827 patent/US9359415B2/en active Active
- 2013-06-06 AU AU2013271545A patent/AU2013271545C1/en active Active
- 2013-06-06 DK DK13801437.8T patent/DK2859015T3/en active
- 2013-06-06 AU AU2013271542A patent/AU2013271542B2/en not_active Ceased
- 2013-06-06 CA CA2869674A patent/CA2869674A1/en not_active Abandoned
- 2013-06-06 HU HUE13801437A patent/HUE037849T2/hu unknown
- 2013-06-06 ES ES13801437.8T patent/ES2675568T3/es active Active
- 2013-06-06 SI SI201331030T patent/SI2859015T1/sl unknown
- 2013-06-06 ME MEP-2018-155A patent/ME03079B/me unknown
- 2013-06-06 US US13/911,834 patent/US9296801B2/en active Active
- 2013-06-06 JP JP2015516219A patent/JP6322626B2/ja not_active Expired - Fee Related
- 2013-06-06 WO PCT/US2013/044551 patent/WO2013184938A2/en not_active Ceased
- 2013-06-06 ES ES13799943.9T patent/ES2667558T3/es active Active
- 2013-06-06 EP EP13801437.8A patent/EP2859015B1/en active Active
- 2013-06-06 JP JP2015516220A patent/JP6234446B2/ja not_active Expired - Fee Related
- 2013-06-06 CA CA2869786A patent/CA2869786A1/en not_active Abandoned
- 2013-06-06 HU HUE18162555A patent/HUE052908T2/hu unknown
- 2013-06-06 WO PCT/US2013/044556 patent/WO2013184942A1/en not_active Ceased
- 2013-06-06 NZ NZ630851A patent/NZ630851A/en not_active IP Right Cessation
- 2013-06-06 EP EP18162555.9A patent/EP3401402B1/en active Active
- 2013-06-06 PT PT138014378T patent/PT2859015T/pt unknown
- 2013-06-06 RS RS20180664A patent/RS57369B1/sr unknown
- 2013-06-06 SM SM20180363T patent/SMT201800363T1/it unknown
- 2013-06-06 HR HRP20180914TT patent/HRP20180914T1/hr unknown
- 2013-06-06 LT LTEP18162555.9T patent/LT3401402T/lt unknown
- 2013-06-06 NZ NZ715099A patent/NZ715099A/en unknown
- 2013-06-06 ES ES13800676.2T patent/ES2675784T3/es active Active
- 2013-06-06 SI SI201331831T patent/SI3401402T1/sl unknown
- 2013-06-06 PL PL13801437T patent/PL2859015T3/pl unknown
- 2013-06-06 SM SM20210007T patent/SMT202100007T1/it unknown
- 2013-06-06 EP EP13800676.2A patent/EP2858672B1/en active Active
- 2013-06-06 NZ NZ630848A patent/NZ630848A/en not_active IP Right Cessation
- 2013-06-06 PT PT181625559T patent/PT3401402T/pt unknown
- 2013-06-06 TR TR2018/09046T patent/TR201809046T4/tr unknown
- 2013-06-06 AU AU2013271541A patent/AU2013271541C1/en not_active Ceased
- 2013-06-06 DK DK18162555.9T patent/DK3401402T3/da active
- 2013-06-06 JP JP2015516221A patent/JP6388408B2/ja active Active
- 2013-06-06 TR TR2018/08753T patent/TR201808753T4/tr unknown
- 2013-06-06 WO PCT/US2013/044552 patent/WO2013184939A2/en not_active Ceased
- 2013-06-06 EP EP13799943.9A patent/EP2874639B1/en active Active
- 2013-06-06 NZ NZ630849A patent/NZ630849A/en unknown
- 2013-06-06 ES ES18162555T patent/ES2842677T3/es active Active
- 2013-06-06 EP EP20201402.3A patent/EP3825405A1/en not_active Withdrawn
- 2013-06-06 RS RS20210004A patent/RS61391B1/sr unknown
- 2013-06-06 PL PL18162555T patent/PL3401402T3/pl unknown
- 2013-06-06 LT LTEP13801437.8T patent/LT2859015T/lt unknown
-
2014
- 2014-02-18 US US14/182,536 patent/US9428563B2/en active Active
-
2015
- 2015-09-01 US US14/841,809 patent/US10023623B2/en active Active
-
2016
- 2016-02-16 US US15/044,310 patent/US10183979B2/en active Active
- 2016-07-25 US US15/218,193 patent/US10407481B2/en active Active
-
2017
- 2017-08-04 JP JP2017151506A patent/JP6545759B2/ja active Active
-
2018
- 2018-06-20 CY CY20181100640T patent/CY1120522T1/el unknown
-
2019
- 2019-06-19 JP JP2019113671A patent/JP7048543B2/ja active Active
- 2019-07-23 US US16/519,231 patent/US20200040053A1/en not_active Abandoned
-
2020
- 2020-12-09 HR HRP20201973TT patent/HRP20201973T1/hr unknown
-
2021
- 2021-01-07 CY CY20211100009T patent/CY1124525T1/el unknown
- 2021-12-02 JP JP2021195887A patent/JP7350041B2/ja active Active
-
2023
- 2023-05-25 JP JP2023085990A patent/JP2023109948A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525216A5 (https=) | ||
| Bednarczyk et al. | β2 Integrins—multi-functional leukocyte receptors in health and disease | |
| KR102739572B1 (ko) | Il-12 및 il-18로의 il-15-기반 융합 | |
| JP2015520193A5 (https=) | ||
| Bell et al. | To fuse or not to fuse: what is your purpose? | |
| Nagae et al. | A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin | |
| Ren et al. | High-level production, solubilization and purification of synthetic human GPCR chemokine receptors CCR5, CCR3, CXCR4 and CX3CR1 | |
| US20070218547A1 (en) | Self assembling proteins for producing extended materials | |
| JP2012532600A5 (https=) | ||
| Li et al. | Crystallizing membrane proteins in lipidic mesophases. A host lipid screen | |
| Zhou et al. | High-Level Production of a Novel Antimicrobial Peptide Perinerin in Escherichia coli by Fusion Expression: Q.-F. Zhou et al. | |
| JP2024541466A5 (https=) | ||
| Cho et al. | Structural basis of flagellar motility regulation by the MogR repressor and the GmaR antirepressor in Listeria monocytogenes | |
| Jarahian et al. | Re-expression of poly/oligo-sialylated adhesion molecules on the surface of tumor cells disrupts their interaction with immune-effector cells and contributes to pathophysiological immune escape | |
| Riley et al. | Borrelia burgdorferi EbfC defines a newly-identified, widespread family of bacterial DNA-binding proteins | |
| Kent et al. | Crystallization and preliminary X-ray diffraction analysis of nuclear transport factor 2 | |
| Safo et al. | Structure of the MecI repressor from Staphylococcus aureus in complex with the cognate DNA operator of mec | |
| Christodoulou et al. | Cloning, overproduction, purification and crystallization of the DNA binding protein HU from the hyperthermophilic eubacterium Thermotoga maritima | |
| JP4892717B2 (ja) | ニワトリキメラ抗体およびその利用 | |
| Vohl et al. | Crystallization and preliminary analysis of the NqrA and NqrC subunits of the Na+-translocating NADH: ubiquinone oxidoreductase from Vibrio cholerae | |
| WO2001085962A1 (en) | Crystallography methods | |
| Adams et al. | MraZ from Escherichia coli: cloning, purification, crystallization and preliminary X-ray analysis | |
| US20200283487A1 (en) | Protein | |
| Tahir et al. | SUMO-fusion and autoinduction-based combinatorial approach for enhanced production of bioactive human interleukin-24 in Escherichia coli | |
| CN113956346A (zh) | 一种重组白介素-15变体 |